JPWO2020231809A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020231809A5
JPWO2020231809A5 JP2021566504A JP2021566504A JPWO2020231809A5 JP WO2020231809 A5 JPWO2020231809 A5 JP WO2020231809A5 JP 2021566504 A JP2021566504 A JP 2021566504A JP 2021566504 A JP2021566504 A JP 2021566504A JP WO2020231809 A5 JPWO2020231809 A5 JP WO2020231809A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021566504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532173A (ja
JP7682102B2 (ja
JP2022532173A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032095 external-priority patent/WO2020231809A1/en
Publication of JP2022532173A publication Critical patent/JP2022532173A/ja
Publication of JPWO2020231809A5 publication Critical patent/JPWO2020231809A5/ja
Publication of JP2022532173A5 publication Critical patent/JP2022532173A5/ja
Application granted granted Critical
Publication of JP7682102B2 publication Critical patent/JP7682102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566504A 2019-05-10 2020-05-08 ヒト化抗ｃｄ１３７抗体およびその使用 Active JP7682102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019086364 2019-05-10
CNPCT/CN2019/086364 2019-05-10
PCT/US2020/032095 WO2020231809A1 (en) 2019-05-10 2020-05-08 Humanized anti-cd137 antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2022532173A JP2022532173A (ja) 2022-07-13
JPWO2020231809A5 true JPWO2020231809A5 (https=) 2023-05-15
JP2022532173A5 JP2022532173A5 (https=) 2023-05-15
JP7682102B2 JP7682102B2 (ja) 2025-05-23

Family

ID=73289535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566504A Active JP7682102B2 (ja) 2019-05-10 2020-05-08 ヒト化抗ｃｄ１３７抗体およびその使用

Country Status (8)

Country Link
US (1) US11203643B2 (https=)
EP (1) EP3966252A4 (https=)
JP (1) JP7682102B2 (https=)
KR (1) KR20220008306A (https=)
CN (1) CN114026120B (https=)
AU (1) AU2020276500A1 (https=)
CA (1) CA3139274A1 (https=)
WO (1) WO2020231809A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
US20060171929A1 (en) * 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
WO2014055967A2 (en) * 2012-10-05 2014-04-10 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
AU2015264528A1 (en) 2014-05-21 2016-11-03 Kyowa Hakko Kirin Co., Ltd. Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2017068183A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd137-receptor agonist proteins
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
MX395639B (es) * 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
CN107982538B (zh) * 2017-12-26 2021-10-22 深圳市体内生物医药科技有限公司 一种药物组合物及其应用
WO2020069382A1 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法

Similar Documents

Publication Publication Date Title
TWI821474B (zh) Ｃｄ３抗體及其藥物用途
JP2021525546A5 (https=)
JP2020023523A5 (https=)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
JP2021516974A5 (https=)
JP2020531048A5 (https=)
JP2021524267A5 (https=)
JP2010511388A5 (https=)
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2017506067A5 (https=)
JP2014526898A5 (https=)
RU2009128064A (ru) Антитела к cd44
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2017535257A5 (https=)
JP2010533498A5 (https=)
JPWO2019147831A5 (https=)
JP2020514277A5 (https=)
JP2018526981A5 (https=)
JP2013520984A5 (https=)
JP2011207882A5 (https=)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2021508707A5 (https=)
JP2012519492A5 (https=)
RU2019104980A (ru) Анти-icos антитела